Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

NCT01678794 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01678794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01678794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2012
Completion date
June 29, 2016
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiorenal syndrome (crs)